Spinocerebellar ataxia (SCA) is an autosomal dominant disease characterised by a slowly progressive lack of coordination, and usually associated with poor gait, hand, speech and eye movements. There are many subtypes of SCA based on which gene is affected, each have their own general age of onset, duration, and typical symptoms. The most well-known subtypes are SCA1, SCA2, SCA3 (Machado-Joseph disease), SCA 6 and SCA7.

This report provides the current prevalent population for Spinocerebellar Ataxia across 14 Major Markets (USA, France, Germany, Italy, Spain, UK, Japan, Netherlands, Norway, China, South Korea, India, Australia, Portugal) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, Spinocerebellar Ataxia patients grouped by type, mobility status and symptoms have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main types and symptoms of Spinocerebellar Ataxia include:

  • Type 1
  • Type 2
  • Type 3
  • Type 6
  • Type 7
  • Wheelchair-dependant
  • Ophthalmoplegia
  • Pyramidal signs

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Ability to quantify patient populations in global Spinocerebellar Ataxia market to target the development of future products, pricing strategies and launch plans.
  • Further insight into the prevalence of the subdivided types of Spinocerebellar Ataxia and identification of patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Identification of Spinocerebellar Ataxia patient sub-populations that require treatment.
  • Better understanding of the specific markets that have the largest number of Spinocerebellar Ataxia patients.